lifesciences
Innopsys

The origin and significance of additional aneuploidy events in couples undergoing preimplantation genetic diagnosis for translocations by array comparative genomic hybridization

Abstract:

Diagnostic application of array comparative genomic hybridization (aCGH) in preimplantation genetic diagnosis for reciprocal and Robertsonian translocations has revealed 55-65% embryos with additional aneuploidies with or without translocation-related imbalances. The occurrence of these extra abnormalities with the balanced form of the translocation reduces the number of embryos suitable for transfer. Eighty-three embryos were followed up on days 5-7 of development from 23 infertile or sub-fertile carriers for whole chromosome and segmental aneuploidies present in addition to the balanced or unbalanced translocations detected on aCGH diagnosis. Embryos were analysed by fluorescence in-situ hybridization (n = 63) and aCGH (n = 20). Meiotic aneuploidy affected 35% of embryos and 47% had mitotic events; 15% had both types. Meiotic and mitotic events were almost equal (60 versus 64), 97 affected whole chromosomes (58 meiotic, 39 mitotic) and 27 were segmental (two meiotic, 25 mitotic). In 85.5% of embryos with whole chromosome additional aneuploidies, the aneuploidy was present throughout or in more than 50% of cells. All embryos diagnosed as abnormal (translocation balanced or unbalanced) after aCGH diagnosis at cleavage stage would have remained unsuitable for transfer if tested at later stages of development. Additional aneuploidies merit full consideration when considering the choice of embryos to transfer.

Credits:

Harita Chevaria1, Sioban SenGupta2, Natalia Shmitova2, Paul Serhal3, Joy Delhanty2

  • 1. Preimplantation Genetics Group, Institute for Women’s Health, 86-96 Chenies Mews, University College London, London WC1E6HX, UK
  • 2. Preimplantation Genetics Group, Institute for Women’s Health, 86-89 Chenies Mews, University College London, London WC1E 6HX, UK
  • 3. The Centre for Reproductive and Genetic Health, 230-232 Great Portland Street, London W1W 5QS, UK

SIÈGE SOCIAL

Parc d'activités Activestre
31390 Carbonne - FRANCE

CONTACT

Tél. +33 561 971 974
Fax +33 561 971 975